A Study to Evaluate the Effectiveness and Safety of CG5503 (Tapentadol) in the Treatment of Chronic Tumor Related Pain Compared With Placebo and Morphine

Pain Clinical Trial

Official title:

A Randomized Withdrawal, Active- and Placebo-controlled, Double-blind, Multi-center Phase III Trial Assessing Safety and Efficacy of Oral CG5503 (Tapentadol) Prolonged Release (PR*) in Subjects With Moderate to Severe Chronic Malignant Tumor-related Pain. *Prolonged Release and is the Recommended Nomenclature for Use in the European Union (EU). ER Means Extended Release and is the Recommended Nomenclature for Use in the United States of America (USA). "PR" is Synonymous With "ER" and is Interchangeable.

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT00505414
• Other study ID #: 672519
• Secondary ID: 2007-001985-34KF
• Status: Terminated
• Phase: Phase 3
• Start date: June 2007
• Est. completion date: May 2009

Study information

• Verified date: October 2019
• Source: Grünenthal GmbH
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to determine whether CG5503 (tapentadol) is effective and safe in the treatment of chronic tumor related pain compared to placebo.

Description:

Normally chronic tumor related pain is controlled when subjects receive repeated doses of opioid analgesics. However, opioid therapy is commonly associated with side effects such as nausea, vomiting, sedation, constipation, addiction, tolerance, and respiratory depression. Tapentadol, a newly synthesized drug with an Prolonged Release (ER) formulation, also acts as a centrally acting pain reliever but has a dual mode of action.

The aim of this trial is to investigate the effectiveness (level of pain control) and safety (side effects) of Tapentadol Prolonged Release (ER) compared to a tablet with no active ingredient drug (placebo) and a corresponding dose of Morphine (an opioid commonly used to treat tumor related pain). This trial is a randomized, double-blind (neither investigator nor patient will know which treatment was received), active- and placebo-controlled, parallel-group, randomized-withdrawal, multicenter trial. To maintain the blind all subjects were re-randomized at the start of the maintenance period. To maintain the blind all tapentadol subjects were re-randomized at the start of the maintenance period. Subjects that received morphine in the titration period continued in the maintenance period on morphine.

The trial includes a 2 week titration phase starting with either 45 mg Morphine Sulfate Controlled Release (CR) twice daily or 100 mg tapentadol ER taken twice daily (bid). Based on effectiveness and side effects participants can up-titrate in steps of 50 mg Tapentadol ER or 15 mg Morphine Sulfate CR to a maximal dose of 250 mg Tapentadol ER bid or 90 mg Morphine Sulfate CR twice daily respectively. If subjects meet the stabilization criteria at the end of the titration phase they will be re-randomized to either placebo or active treatment and will continue 4 weeks at the last dose level in the maintenance phase.

Assessments of pain relief, defined as a responder include the pain intensity numeric rating scale (NRS). The Patient Global Impression of Change scale (PGIC) will also be used as a secondary efficacy endpoint. Safety evaluations include monitoring of adverse events, physical examinations, and clinical laboratory tests. Venous blood samples will be collected for the determination of serum concentrations of tapentadol.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 136
• Est. completion date: May 2009
• Est. primary completion date: February 2009
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• A signed informed consent document.

• Male and non-pregnant, non-lactating female subjects.

• Female subjects must be post menopausal, surgically sterile, or practicing an effective method of birth control and continue to do so throughout the trial.

• At least 18 years of age.

• Have chronic malignant tumor-related pain

• Are opioid-naïve or have been pretreated with an equianalgesic dose range equivalent of up to 160 mg oral morphine per day and are dissatisfied with prior treatment.

• Have a mean pain intensity of at least 5 points on an 11-point Numeric Rating Scale (where 0 indicates no pain and 10 indicates worst possible pain).

• Have an expected course of the disease such that the pain that will permit compliance with the trial protocol over the entire trial period.

Exclusion Criteria:

• Have a life-long history of seizure disorder or epilepsy.

• Have had any of the following within one year: mild/moderate traumatic brain injury, stroke, and transient ischemic attack.

• Have had severe traumatic brain injury within 15 years (consisting of = 1 of the following: brain contusion, intracranial hematoma, and either unconsciousness or post-traumatic amnesia lasting for more than 24 hours) or residual sequelae suggesting transient changes in consciousness.

• Have a known history and/or presence of cerebral metastases.

• Have moderately or severely impaired hepatic function.

• Have laboratory values reflecting inadequate hepatic function.

• Have thrombopenia, leucopenia or hypercalcemia

• Have severely impaired renal function.

• Having uncontrolled hypertension

• Having clinically relevant history of hypersensitivity, allergy or contraindications to morphine or any of the excipients.

• Have chronic hepatitis B or hepatitis C, or Human Immunodeficiency Virus (HIV).

• Subjects currently undergoing the following concomitant therapy: radiotherapy, pain inducing chemotherapy, anti-parkinsonian drugs, neuroleptics, monoamine oxidase inhibitors, serotonin norepinephrine re-uptake inhibitors (SNRI) or any other analgesic therapy than investigational medication or rescue medication during the trial. Selective serotonin re-uptake inhibitor (SSRI) treatments are allowed if taken for at least 30 days before the screening period of the trial at an unchanged dose.

Related Conditions & MeSH terms

• Cancer
• Cancer Pain
• Neoplasm
• Pain

Intervention

Drug:
• Tapentadol in the Titration Phase

• Morphine in the Maintenance Phase
Participant started the trials with 45 mg morphine controlled release twice daily. Upward titration could then occur at a minimum of 3-day intervals in increments of 15 mg morphine twice daily. The maximum dose of morphine controlled release was 90 mg twice daily. Downward titration (but not below 45 mg twice daily) was permitted. In the maintenance phase participants continued on the dose level established in titration phase. Participants randomized to the morphine arm remained on morphine if they qualified for the maintenance phase of the study. The participants were maintained on the dose established at the end of the titration phase. The adverse events listed were documented in the maintenance phase.
• Matching Placebo in the Maintenance Phase after Tapentadol in the Titration Phase
Participant randomized to placebo in the maintenance phase received 100 mg tapentadol prolonged release twice daily for 3 days to taper them off of the tapentadol dose they had received in the titration period. From the fourth day of the maintenance period onwards they received placebo twice daily.
• Tapentadol in the Maintenance Phase
The participants re-randomized to receive tapentadol prolonged release in the maintenance phase were maintained on the dose established in the titration phase.
• Morphine in the Titration Phase
After signing informed consent eligible subjects were randomized to receive morphine controlled release. The oral medication was taken twice daily, morning and evening every 12 hours (with a minimum of 6 hours between doses). Participant started the trials with 45 mg morphine controlled release twice daily. Upward titration could then occur at a minimum of 3-day intervals in increments of 15 mg morphine twice daily. The maximum dose of morphine controlled release was 90 mg twice daily. Downward titration (but not below 45 mg twice daily) was permitted.

Locations

Country	Name	City	State
Argentina	54009	Ciudad de Buenos Aires
Argentina	054003	La Plata	Buenos Aires
Argentina	054012	Pergamino	Buenos Aires
Argentina	054022	Quilmes	Buenos Aires
Argentina	054010	Rosario	Santa Fe
Argentina	054013	Rosario	Santa Fe
Argentina	054005	San Miguel de Tucuman	Tucuman
Argentina	054015	Santa Fe
Argentina	054008	Villa Dominico	Buenos Aires
Chile	056006	Coquimbo
Chile	056005	Santiago
Chile	056008	Santiago
Chile	056011	Santiago
Chile	056003	Talcahuano
Chile	056004	Temuco
Chile	056012	Valparaiso
France	033002	Nice Cedex 1
France	033015	Orléans- Cedex
France	033001	Villejuif Cedex
Latvia	371001	Daugavpils
Latvia	371002	Riga
Ukraine	380015	Cherkasy
Ukraine	380011	Donetsk
Ukraine	380012	Donetsk
Ukraine	380002	Kharkiv
Ukraine	380008	Kharkiv
Ukraine	380001	Kiev
Ukraine	380013	Kiev
Ukraine	380009	Lviv
Ukraine	380010	Poltava
United States	001015	Canton	Ohio
United States	001010	Cedarhurst	New York
United States	001002	Elkhart	Indiana
United States	001003	Glens Falls	New York
United States	001013	Saint Petersburg	Florida
United States	001001	Shreveport	Louisiana
United States	001004	Winston-Salem	North Carolina

Sponsors (2)

Lead Sponsor	Collaborator
Grünenthal GmbH	Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Countries where clinical trial is conducted

United States,  Argentina,  Chile,  France,  Latvia,  Ukraine, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Responder Rates in Maintenance Period	A "responder" is a participant in the study that: completed 28 days of the maintenance phase; had a numeric rating scale score below 5 on the 11 point scale (where 0 indicates no pain and 10 indicates worst possible pain. This twice daily current pain score was averaged over Day 18 to Day 43.; did not use more than 30 mg of rescue medication per day on average in the 28 day (excluding the first 3 days) maintenance period (from Day 18 to Day 43).; A participant that met all 3 of the above-mentioned criteria is counted as a responder, in other words the participant benefited from the assigned drug treatment. A participant that fails to meet at least 1 of the 3 criteria is not counted as a responder.	End of the 4 week Maintenance Phase (Day 43)
Secondary	Patient Global Impression of Change (PGIC)	The Patient Global Impression of Change (PGIC) is an instrument where the participant indicates their perceived change at the end of a treatment phase. The overall participant status assessed using Patient Global Impression of Change (PGIC) self-assessment questionnaire which was used by participants to report on 7 categories listed as follows; Very Much Improved, Much Improved, Minimally Improved, No Change, Minimally Worse, Much Worse and Very Much Worse in tapentadol and morphine at Day 15 (Start of Maintenance Phase) and repeated in participants completing the Maintenance Phase in the Matching Placebo, Tapentadol and Morphine (Day 43).	Day 15 corresponds with PGIC at end of titration phase; Day 43 corresponds with PGIC at end of maintenance phase